Histogen Inc., a clinical-stage therapeutics company, focuses on developing therapeutics based upon the products of fibroblast cells grown under simulated embryonic conditions. It offers HST-001, a hair stimulating complex that is in Phase 1b/2a clinical trial for the treatment of androgenic alopecia (hair loss); HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; and Emricasan, an orally active pan-caspase inhibitor that is in Phase 1 clinical trial for the treatment of COVID-19. The company's pre-clinical programs include HST-004, a cell conditioned media (CCM) solution to treat spinal disc repair; and HST-002, a human-derived collagen and extracellular matrix dermal filler for the treatment of facial folds and wrinkles. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
IPO Year: 2013
Exchange: NASDAQ
Website: histogen.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/30/2021 | $2.40 | Buy | HC Wainwright & Co. |
HC Wainwright & Co. initiated coverage of Histogen with a rating of Buy and set a new price target of $2.40
Canaccord Genuity reiterated coverage of Histogen with a rating of Buy and set a new price target of $4.00 from $5.00 previously
Canaccord Genuity initiated coverage of Histogen with a rating of Buy and set a new price target of $5.00
Canaccord Genuity initiated coverage of Histogen with a rating of Buy and set a new price target of $5.00
Canaccord Genuity initiated coverage of Histogen with a rating of Buy